Advanced search
Publication Cover
The World Journal of Biological Psychiatry Volume 22, 2021 - Issue 7
Submit an article Journal homepage
2,088
Views
20
CrossRef citations to date
0
Altmetric
Review Articles

A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?

Seetal Dodda IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia;b Department of Psychiatry, University of Melbourne, Melbourne, Australia;c Barwon Health, University Hospital Geelong, Geelong, Australia;d Centre for Youth Mental Health, University of Melbourne, Melbourne, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7918-4636View further author information
ORCID Icon,
Michael Bauere Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, GermanyORCID Iconhttps://orcid.org/0000-0002-2666-859XView further author information
ORCID Icon,
Andre F. Carvalhoa IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia;f Department of Psychiatry, University of Toronto and Centre for Addiction and Mental Health (CAMH), Toronto, CanadaORCID Iconhttps://orcid.org/0000-0002-2500-5671View further author information
ORCID Icon,
Harris Eyrea IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia;g Discipline of Psychiatry, School of Medicine, The University of Adelaide, Adelaide, AustraliaView further author information
,
Maurizio Favah Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USAView further author information
,
Siegfried Kasperi Center for Brain Research, Medical University of Vienna, Vienna, AustriaORCID Iconhttps://orcid.org/0000-0001-8278-191XView further author information
ORCID Icon,
Sidney H. Kennedyj Department of Psychiatry, University of Toronto and Centre for Depression and Suicide Studies, St Michael’s Hospital, Toronto, CanadaORCID Iconhttps://orcid.org/0000-0001-5339-7185View further author information
ORCID Icon,
Jon-Paul Khook Toowong Specialist Clinic, Toowong, AustraliaView further author information
,
Carlos Lopez Jaramillol Department of Psychiatry, Universidad de Antioquia, Medellín, ColombiaView further author information
,
Gin S. Malhim Department of Psychiatry, Faculty of Medicine and Health, Northern Clinical School, The University of Sydney, Sydney, Australia;n Academic Department of Psychiatry, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Australia;o CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, AustraliaView further author information
,
Roger S. McIntyref Department of Psychiatry, University of Toronto and Centre for Addiction and Mental Health (CAMH), Toronto, Canada;p Mood Disorders Psychopharmacology Unit, Toronto, Canada;q Brain and Cognition Discovery Foundation, Toronto, CanadaView further author information
,
Philip B. Mitchellr School of Psychiatry, University of New South Wales, and Black Dog Institute, Sydney, AustraliaORCID Iconhttps://orcid.org/0000-0002-7954-5235View further author information
ORCID Icon,
Angela Marianne Paredes Castroa IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, AustraliaORCID Iconhttps://orcid.org/0000-0002-4715-3798View further author information
ORCID Icon,
Aswin Ratheeshs Orygen The National Centre of Excellence in Youth Mental Health, Parkville, Australia;d Centre for Youth Mental Health, University of Melbourne, Melbourne, AustraliaView further author information
,
Emanuel Severuse Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, GermanyORCID Iconhttps://orcid.org/0000-0002-9135-1679View further author information
ORCID Icon,
Trisha Suppest VA Health Care System, Palo Alto, CA, and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USAView further author information
,
Madhukar H. Trivediu Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USAView further author information
,
Michael E. Thasev Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAView further author information
,
Lakshmi N. Yathamw Department of Psychiatry, University of British Columbia, Vancouver, CanadaView further author information
,
Allan H. Youngx Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London & South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Beckenham, Kent, UKORCID Iconhttps://orcid.org/0000-0003-2291-6952View further author information
ORCID Icon &
Michael Berka IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Australia;b Department of Psychiatry, University of Melbourne, Melbourne, Australia;c Barwon Health, University Hospital Geelong, Geelong, Australia;s Orygen The National Centre of Excellence in Youth Mental Health, Parkville, Australia;y The Florey Institute of Neuroscience and Mental Health, Parkville, Australia;d Centre for Youth Mental Health, University of Melbourne, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0002-5554-6946View further author information
ORCID Icon show all
Pages 483-494 | Received 16 Jun 2020, Accepted 10 Nov 2020, Published online: 08 Dec 2020

References

  • Agosti V. 2014. Predictors of remission from chronic depression: a prospective study in a nationally representative sample. Compr Psychiatry. 55(3):463–467.
  • Angst J, Adolfsson R, Benazzi F, Gamma A, Hantouche E, Meyer TD, Skeppar P, Vieta E, Scott J. 2005. The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord. 88(2):217–233.
  • Association. AP. 2013. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association.
  • Aznar-Lou I, Iglesias-Gonzalez M, Gil-Girbau M, Serrano-Blanco A, Fernandez A, Penarrubia-Maria MT, Sabes-Figuera R, Murrugarra-Centurion AG, March-Pujol M, Bolivar-Prados M, et al. 2018. Impact of initial medication non-adherence to SSRIs on medical visits and sick leaves. J Affect Disord. 226:282–286.
  • Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, et al. 2019. Results of the European Group for the Study of Resistant Depression (GSRD) – basis for further research and clinical practice. World J Biol Psychiatry. 20(6):427–448.
  • Bauer M. 2007. Updated WFSBP guidelines for the biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 8(2):66.
  • Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Moller HJ. 2007. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 8(2):67–104.
  • Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ. 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 14(5):334–385.
  • Bauer M, Severus E, Kohler S, Whybrow PC, Angst J, Moller HJ. 2015. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 16(2):76–95.
  • Bauer M, Severus E, Moller HJ, Young AH. 2017. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int J Psychiatry Clin Pract. 21(3):166–176.
  • Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. 2002a. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 3(1):5–43.
  • Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. 2002b. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 3(2):69–86.
  • Berk M, Dodd S, Callaly P, Berk L, Fitzgerald P, de Castella AR, Filia S, Filia K, Tahtalian S, Biffin F, et al. 2007. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. J Affect Disord. 103(1–3):181–186.
  • Berlim MT, Turecki G. 2007. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 17(11):696–707.
  • Bock C, Bukh JD, Vinberg M, Gether U, Kessing LV. 2010. The influence of comorbid personality disorder and neuroticism on treatment outcome in first episode depression. Psychopathology. 43(3):197–204.
  • Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. 2019. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 20(1):37–47.
  • Carvalho AF, Berk M, Hyphantis TN, McIntyre RS. 2014. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom. 83(2):70–88.
  • Carvalho AF, McIntyre RS, Dimelis D, Gonda X, Berk M, Nunes-Neto PR, Cha DS, Hyphantis TN, Angst J, Fountoulakis KN. 2014. Predominant polarity as a course specifier for bipolar disorder: a systematic review. J Affect Disord. 163:56–64.
  • Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. 2010. RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 16(5):322–325.
  • Clemens NA. 2007. Deconstructing depression. J Psychiatr Pract. 13(2):106–108.
  • Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, Caliman-Fontes AT, Echegaray MVF, Bandeira ID, Silva SS, et al. 2020. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 264:527–534.
  • Dodd S, Berk M. 2004. Predictors of antidepressant response: a selective review. Int J Psychiatry Clin Pract. 8(2):91–100.
  • Edwards SJ, Hamilton V, Nherera L, Trevor N. 2013. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol Assess. 17(54):1–190.
  • Ellis P. 2004. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry. 38(6):389–407.
  • Ellison JM, Harney PA. 2000. Treatment-resistant depression and the collaborative treatment relationship. J Psychother Pract Res. 9(1):7–17.
  • Emond SK, Ollendorf DA, Colby JA, Reed SJ, Pearson SD. 2013. Evaluating the evidence on comparative effectiveness and value of management options for treatment-resistant depression. Postgrad Med. 125(6):7–16.
  • Ereshefsky L, Saragoussi D, Despiegel N, Hansen K, Francois C, Maman K. 2010. The 6-month persistence on SSRIs and associated economic burden. J Med Econ. 13(3):527–536.
  • Fiore V, Marci M, Poggi A, Giagulli VA, Licchelli B, Iacoviello M, Guastamacchia E, De Pergola G, Triggiani V. 2015. The association between diabetes and depression: a very disabling condition. Endocrine. 48(1):14–24.
  • Firth J, Ward PB, Stubbs B. 2019. Editorial: lifestyle psychiatry. Front Psychiatry. 10:597.
  • Harris MG, Kazdin AE, Chiu WT, Sampson NA, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Altwaijri Y, Andrade LH, Cardoso G, et al. 2020. Findings From World Mental Health Surveys of the Perceived Helpfulness of Treatment for Patients With Major Depressive Disorder. JAMA Psychiatry. 77(8):830.
  • Heimann H. 1974. Therapy-resistant depressions: symptoms and syndromes. Contributions to symptomatology and syndromes. Pharmakopsychiatr Neuropsychopharmakol. 7(3):139–144.
  • Hetrick SE, Parker AG, Hickie IB, Purcell R, Yung AR, McGorry PD. 2008. Early identification and intervention in depressive disorders: towards a clinical staging model. Psychother Psychosom. 77(5):263–270.
  • Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, Ll A, et al. 2015. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 98(2):127–134.
  • Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE, Jr., Lewis L, McElroy SL, Post RM, Rapport DJ, et al. 2000. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 157(11):1873–1875.
  • Holtzmann J, Richieri R, Saba G, Allaili N, Bation R, Moliere F, Nieto I, Bellivier F, Bennabi D, Bubrovszky M, et al. 2016. [How to define treatment-resistant depression?]. Presse Med. 45(3):323–328.
  • Howland RH. 1993. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. J Clin Psychiatry. 54(2):47–54.
  • Jain FA, Hunter AM, Brooks JO, Leuchter AF. 2013. Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depress Anxiety. 30(7):624–630.
  • Jukic MM, Haslemo T, Molden E, Ingelman-Sundberg M. 2018. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry. 175(5):463–470.
  • Kennedy SH, Ceniti AK. 2018. Unpacking major depressive disorder: from classification to treatment selection. Can J Psychiatry. 63(5):308–313.
  • Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM. et al. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 61(9):540–560.
  • Kennedy SH, Lam RW, Parikh SV, Patten SB, Ravindran AV. 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord. 117(Suppl 1):S1–S2.
  • Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV. 2009. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 117(Suppl 1):S26–S43.
  • Lam RW, Kennedy SH, Parikh SV, MacQueen GM, Milev RV, Ravindran AV. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. Can J Psychiatry. 61(9):506–509.
  • Lam RW, McIntosh D, Wang J, Enns MW, Kolivakis T, Michalak EE, Sareen J, Song WY, Kennedy SH, MacQueen GM, et al. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 1. disease burden and principles of care. Can J Psychiatry. 61(9):510–523.
  • Lam RW, Michalak EE, Yatham LN. 2009. A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. BMC Psychiatry. 9(1):78.
  • Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, Lima CS, Jesus-Nunes AP, Guerreiro-Costa LNF, Marback RF, et al. 2020. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. doi:https://doi.org/10.1007/s00406-020-01110-5
  • Leone T, Coast E, Narayanan S, de Graft Aikins A. 2012. Diabetes and depression comorbidity and socio-economic status in low and middle income countries (LMICs): a mapping of the evidence. Global Health. 8:39.
  • Macneil CA, Hasty MK, Conus P, Berk M. 2012. Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. BMC Med. 10:111.
  • MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Lieshout RJ, Kennedy SH, Lam RW, Milev RV, Parikh SV, et al. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. special populations: youth, women, and the elderly. Can J Psychiatry. 61(9):588–603.
  • Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M, Lyndon B, Mulder R, Murray G, et al. 2015. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 49(12):1087–1206.
  • McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, Alsuwaidan M, Baskaran A. 2013. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 30(6):515–527.
  • McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, Barakat M, Miguelez M. 2014. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 156:1–7.
  • McIntyre RS, Xiao HX, Syeda K, Vinberg M, Carvalho AF, Mansur RB, Maruschak N, Cha DS. 2015. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs. 29(7):577–589.
  • Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, Modirrousta M, Patry S, Vila-Rodriguez F, Lam RW, et al. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. neurostimulation treatments. Can J Psychiatry. 61(9):561–575.
  • Moreno-Ortega M, Kangarlu A, Lee S, Perera T, Kangarlu J, Palomo T, Glasser MF, Javitt DC. 2020. Parcel-guided rTMS for depression. Transl Psychiatry. 10(1):283.
  • Mueller TI, Lavori PW, Keller MB, Swartz A, Warshaw M, Hasin D, Coryell W, Endicott J, Rice J, Akiskal H. 1994. Prognostic effect of the variable course of alcoholism on the 10-year course of depression. Am J Psychiatry. 151(5):701–706.
  • Nanni V, Uher R, Danese A. 2012. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry. 169(2):141–151.
  • Newport DJ, Schatzberg AF, Nemeroff CB. 2016. Whither ketamine as an antidepressant: panacea or toxin? Depress Anxiety. 33(8):685–688.
  • NICE Guidance. 2018. Depression in adults: recognition and management; [accessed 2010 May 16]. https://www.nice.org.uk/guidance/cg90.
  • Oliveira P, Ribeiro J, Donato H, Madeira N. 2017. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 16:17.
  • Parikh SV, Quilty LC, Ravitz P, Rosenbluth M, Pavlova B, Grigoriadis S, Velyvis V, Kennedy SH, Lam RW, MacQueen GM, et al. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments. Can J Psychiatry. 61(9):524–539.
  • Parker G. 2016. Managing patients who are ultra-rapid metabolisers of antidepressant medications. Australas Psychiatry. 24(4):374–375.
  • Parker G. 2018. The benefits of antidepressants: news or fake news? Br J Psychiatry. 213(2):454–455.
  • Philip NS, Carpenter LL, Tyrka AR, Price LH. 2010. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 11(5):709–722.
  • Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, et al. 2019. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 176(6):428–438.
  • Rafi MS, Naqvi SB, Khan MU, Fayyaz M, Ashraf N, Khan MA, Ahmad A, Dhingra S. 2015. Evaluation of potential drug-drug interactions with antidepressants in two tertiary care hospitals. J Clin Diagn Res. 9(7):FC05–FC08.
  • Ravindran AV, Balneaves LG, Faulkner G, Ortiz A, McIntosh D, Morehouse RL, Ravindran L, Yatham LN, Kennedy SH, Lam RW, et al. 2016. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. complementary and alternative medicine treatments. Can J Psychiatry. 61(9):576–587.
  • Ruberto VL, Jha MK, Murrough JW. 2020. Pharmacological treatments for patients with treatment-resistant depression. Pharmaceuticals. 13(6):116.
  • Sackeim HA. 2001. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 62(Suppl 16):10–17.
  • Sarris J, O’Neil A, Coulson CE, Schweitzer I, Berk M. 2014. Lifestyle medicine for depression. BMC Psychiatry. 14:107.
  • Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM, Jr., Williams LM. 2015. ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am J Psychiatry. 172(8):751–759.
  • Scott J, Leboyer M, Hickie I, Berk M, Kapczinski F, Frank E, Kupfer D, McGorry P. 2013. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry. 202(4):243–245.
  • Sheehan DV, Harnett-Sheehan K, Ba R. 1996. The measurement of disability. Int Clin Psychopharmacol. 11(Suppl 3):89–95.
  • Singh AB, Bousman CA, Ng CH, Byron K, Berk M. 2012. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry. 2(11):e198–e198.
  • Stringhini S, Sabia S, Shipley M, Brunner E, Nabi H, Kivimaki M, Singh-Manoux A. 2010. Association of socioeconomic position with health behaviors and mortality. JAMA. 303(12):1159–1166.
  • Suehs BT, Argo TR, Bendele SD, Crismon LM, Trivedi MH, Kurian B. 2008. Texas medication algorithm project procedural manual: major depressive disorder algorithm; [accessed 2010 Feb 9]. http://www.dshs.state.tx.us/mhprograms/TIMA.shtm.
  • Thase ME. 2011. Treatment-resistant depression: prevalence, risk factors, and treatment strategies. J Clin Psychiatry. 72(5):e18.
  • Thomas SJ, Shin M, McInnis MG, Bostwick JR. 2015. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy. 35(4):433–449.
  • Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM. 2014. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry. 26(3):222–232.
  • van Belkum SM, Geugies H, Lysen TS, Cleare AJ, Peeters F, Penninx B, Schoevers RA, Ruhe HG. 2018. Validity of the Maudsley Staging Method in predicting treatment-resistant depression outcome using the Netherlands Study of Depression and Anxiety. J Clin Psychiatry. 79(1):17m11475.
  • van der Schans J, Hak E, Postma M, Breuning L, Brouwers J, Ditters K, Jansen PAF, Kok RM, Maring JG, van Marum R, et al. 2019. Effects of pharmacogenetic screening for CYP2D6 among elderly starting therapy with nortriptyline or venlafaxine: a pragmatic randomized controlled trial (CYSCE Trial). J Clin Psychopharmacol. 39(6):583–590.
  • Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, et al. 2020. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry. 81(3):19m12891.
  • Wei Y, Chang L, Hashimoto K. 2020. A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav. 190:172870.
  • World Health Organisation. 2018. International clasification of disease 11th Revision. icd.who.int Geneva: WHO.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.